ACSS3

Summary

ACSS3 (acyl-CoA synthetase short chain family member 3, HGNC:24723) is a protein-coding gene on chromosome 12q21.31, encoding Acyl-CoA synthetase short-chain family member 3, mitochondrial (Q9H6R3). Catalyzes the synthesis of acetyl-CoA from short-chain fatty acids.

Enables propionate-CoA ligase activity. Predicted to be involved in ketone body biosynthetic process. Located in mitochondrial matrix.

Source: NCBI Gene 79611 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 123 total — 5 pathogenic, 1 likely-pathogenic
• MANE Select transcript: NM_024560

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24723
Approved symbol	ACSS3
Name	acyl-CoA synthetase short chain family member 3
Location	12q21.31
Locus type	gene with protein product
Status	Approved
Aliases	FLJ21963
Ensembl gene	ENSG00000111058
Ensembl biotype	protein_coding
OMIM	614356
Entrez	79611

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 9 protein_coding, 3 retained_intron, 3 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000261206, ENST00000546664, ENST00000548058, ENST00000548324, ENST00000548387, ENST00000549175, ENST00000551745, ENST00000616449, ENST00000650935, ENST00000651903, ENST00000903501, ENST00000903502, ENST00000903503, ENST00000965759, ENST00000965760, ENST00000965761

RefSeq mRNA: 3 — MANE Select: NM_024560 NM_001330242, NM_001330243, NM_024560

CCDS: CCDS81716, CCDS9022

Canonical transcript exons

ENST00000548058 — 16 exons

Exon	Start	End
ENSE00000752686	81143107	81143247
ENSE00000752687	81151844	81151924
ENSE00000937078	81134816	81135004
ENSE00002358894	81254857	81261210
ENSE00002376408	81078079	81078431
ENSE00003471176	81216901	81216996
ENSE00003527509	81139131	81139265
ENSE00003685099	81109560	81109704
ENSE00003712258	81253495	81253670
ENSE00003715269	81220013	81220076
ENSE00003721399	81199341	81199444
ENSE00003725784	81253307	81253406
ENSE00003732405	81152001	81152096
ENSE00003733943	81231057	81231138
ENSE00003736576	81174788	81174939
ENSE00003744043	81233349	81233471

Expression profiles

Bgee: expression breadth ubiquitous, 228 present calls, max score 91.39.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.5505 / max 326.8916, expressed in 1043 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
127126	4.8097	926
127125	2.1637	827
127124	0.4873	328
127123	0.0898	35

Top tissues by expression

272 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
germinal epithelium of ovary	UBERON:0001304	91.39	gold quality
parotid gland	UBERON:0001831	90.96	gold quality
liver	UBERON:0002107	89.93	gold quality
calcaneal tendon	UBERON:0003701	89.35	gold quality
corpus epididymis	UBERON:0004359	89.17	gold quality
left adrenal gland	UBERON:0001234	89.05	gold quality
right lobe of liver	UBERON:0001114	89.03	gold quality
caput epididymis	UBERON:0004358	88.73	gold quality
right adrenal gland cortex	UBERON:0035827	88.59	gold quality
left adrenal gland cortex	UBERON:0035825	88.41	gold quality
right adrenal gland	UBERON:0001233	88.31	gold quality
adrenal cortex	UBERON:0001235	87.66	gold quality
sural nerve	UBERON:0015488	87.55	gold quality
adrenal gland	UBERON:0002369	87.03	gold quality
left ovary	UBERON:0002119	86.88	gold quality
stromal cell of endometrium	CL:0002255	86.50	gold quality
tibial nerve	UBERON:0001323	85.97	gold quality
subcutaneous adipose tissue	UBERON:0002190	85.93	gold quality
adipose tissue	UBERON:0001013	85.85	gold quality
right atrium auricular region	UBERON:0006631	85.50	gold quality
ovary	UBERON:0000992	85.26	gold quality
right ovary	UBERON:0002118	85.02	gold quality
heart left ventricle	UBERON:0002084	84.99	gold quality
connective tissue	UBERON:0002384	84.86	gold quality
gall bladder	UBERON:0002110	84.77	gold quality
cardiac ventricle	UBERON:0002082	84.53	gold quality
apex of heart	UBERON:0002098	84.43	gold quality
parietal pleura	UBERON:0002400	84.30	gold quality
cardiac atrium	UBERON:0002081	84.02	gold quality
adult mammalian kidney	UBERON:0000082	83.70	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	11.88
E-MTAB-9388	yes	11.10
E-GEOD-124858	no	89.08

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

56 targeting ACSS3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-6715A-3P	99.83	68.05	1473
HSA-MIR-4760-5P	99.80	69.88	1619
HSA-MIR-2052	99.79	69.37	2031
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-548O-3P	99.74	69.30	2228
HSA-MIR-4255	99.72	67.70	1541
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363

Literature-anchored findings (GeneRIF, showing 4)

• This report is the first to indicate ACSS3 as a biomarker of GCa prognosis and that targeting ACSS3 in GCa patients might be therapeutically valuable. (PMID:29493120)
• ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3. (PMID:33391508)
• Genome-wide assessment reveals a significant association between ACSS3 and physical activity. (PMID:36510703)
• ACSS3 regulates the metabolic homeostasis of epithelial cells and alleviates pulmonary fibrosis. (PMID:37979225)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	acss3	ENSDARG00000032218
mus_musculus	Acss3	ENSMUSG00000035948
rattus_norvegicus	Acss3	ENSRNOG00000004448
drosophila_melanogaster	CG6432	FBGN0039184

Paralogs (13): ACSM3 (ENSG00000005187), ACSM2B (ENSG00000066813), AACS (ENSG00000081760), ACSS2 (ENSG00000131069), ACSS1 (ENSG00000154930), AASDH (ENSG00000157426), ACSM1 (ENSG00000166743), ACSF2 (ENSG00000167107), ACSM6 (ENSG00000173124), ACSF3 (ENSG00000176715), ACSM5 (ENSG00000183549), ACSM2A (ENSG00000183747), ACSM4 (ENSG00000215009)

Protein

Protein identifiers

Acyl-CoA synthetase short-chain family member 3, mitochondrial — Q9H6R3 (reviewed: Q9H6R3)

Alternative names: Acetate–CoA ligase 3, Acyl-CoA synthetase short-chain family member 3, Propionate–CoA ligase

All UniProt accessions (4): A0A0B4J1R2, Q9H6R3, F8VZB4, H0YII9

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the synthesis of acetyl-CoA from short-chain fatty acids. Propionate is the preferred substrate. Can utilize acetate and butyrate with a much lower affinity.

Subcellular location. Mitochondrion matrix.

Similarity. Belongs to the ATP-dependent AMP-binding enzyme family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9H6R3-1	1	yes
Q9H6R3-2	2

RefSeq proteins (3): NP_001317171, NP_001317172, NP_078836* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000873	AMP-dep_synth/lig_dom	Domain
IPR020845	AMP-binding_CS	Conserved_site
IPR025110	AMP-bd_C	Domain
IPR032387	ACAS_N	Domain
IPR042099	ANL_N_sf	Homologous_superfamily
IPR045851	AMP-b_sf	Homologous_superfamily

Pfam: PF00501, PF13193, PF16177

Catalyzed reactions (Rhea), 3 shown:

• propanoate + ATP + CoA = propanoyl-CoA + AMP + diphosphate (RHEA:20373)
• acetate + ATP + CoA = acetyl-CoA + AMP + diphosphate (RHEA:23176)
• butanoate + ATP + CoA = butanoyl-CoA + AMP + diphosphate (RHEA:46172)

UniProt features (13 total): binding site 7, modified residue 2, transit peptide 1, chain 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H6R3-F1	87.93	0.71

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (7): 227–230; 425–427; 446–451; 539; 554; 565; 624

Post-translational modifications (2): 524, 518

Function

Pathways and Gene Ontology

Reactome pathways

10 pathways

ID	Pathway
R-HSA-77111	Synthesis of Ketone Bodies
R-HSA-9841922	MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
R-HSA-1430728	Metabolism
R-HSA-212165	Epigenetic regulation of gene expression
R-HSA-556833	Metabolism of lipids
R-HSA-74160	Gene expression (Transcription)
R-HSA-74182	Ketone body metabolism
R-HSA-9818564	Epigenetic regulation of gene expression by MLL3 and MLL4 complexes
R-HSA-9851695	Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes
R-HSA-9917777	Epigenetic regulation by WDR5-containing histone modifying complexes

MSigDB gene sets: 76 (showing top): WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN, GOBP_GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, chr12q21, GOBP_LIPID_METABOLIC_PROCESS, DOUGLAS_BMI1_TARGETS_DN, GOBP_LIPID_BIOSYNTHETIC_PROCESS, CAIRO_HEPATOBLASTOMA_UP, GOBP_FATTY_ACID_DERIVATIVE_BIOSYNTHETIC_PROCESS, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, GOBP_FATTY_ACID_DERIVATIVE_METABOLIC_PROCESS, HUANG_DASATINIB_RESISTANCE_DN, CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_UP, GOCC_MITOCHONDRIAL_MATRIX

GO Biological Process (2): ketone body biosynthetic process (GO:0046951), lipid metabolic process (GO:0006629)

GO Molecular Function (7): acetyl-CoA synthetase activity (GO:0003987), ATP binding (GO:0005524), medium-chain fatty acid-CoA ligase activity (GO:0031956), propionate-CoA ligase activity (GO:0050218), nucleotide binding (GO:0000166), protein binding (GO:0005515), ligase activity (GO:0016874)

GO Cellular Component (2): mitochondrion (GO:0005739), mitochondrial matrix (GO:0005759)

Reactome top-level categories

Rollup of top-8 pathways:

Category	Pathways
Ketone body metabolism	1
Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes	1
Gene expression (Transcription)	1
Metabolism	1
Metabolism of lipids	1
Epigenetic regulation by WDR5-containing histone modifying complexes	1
Epigenetic regulation of gene expression by MLL3 and MLL4 complexes	1
Epigenetic regulation of gene expression	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
small molecule biosynthetic process	1
fatty acid derivative biosynthetic process	1
primary metabolic process	1
CoA-ligase activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
fatty acid-CoA ligase activity	1
short-chain fatty acid-CoA ligase activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
catalytic activity	1
cytoplasm	1
intracellular membrane-bounded organelle	1
mitochondrion	1
intracellular organelle lumen	1

Protein interactions and networks

STRING

1953 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ACSS3	AASDH	Q4L235	530
ACSS3	ACLY	P53396	519
ACSS3	HACD4	Q5VWC8	491
ACSS3	PPFIA2	O75334	480
ACSS3	LLPH	Q9BRT6	462
ACSS3	MSRB3	Q8IXL7	462
ACSS3	RFX8	Q6ZV50	460
ACSS3	ACAA2	P42765	450
ACSS3	ACOT8	O14734	449
ACSS3	HMGCL	P35914	429
ACSS3	FASN	P49327	425
ACSS3	STRADB	Q9C0K7	418
ACSS3	ATP5MK	Q96IX5	418
ACSS3	SPATA25	Q9BR10	417
ACSS3	PCCA	P05165	411

IntAct

5 interactions, top by confidence:

A	B	Type	Score
OPTN	ACSS3	psi-mi:“MI:0915”(physical association)	0.560
LEFTY2	ACSS3	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (11): ACSS3 (Affinity Capture-MS), ACSS3 (Proximity Label-MS), ACSS3 (Co-fractionation), ACSS3 (Co-fractionation), ACSS3 (Co-fractionation), ACSS3 (Affinity Capture-MS), ACSS3 (Affinity Capture-MS), ACSS3 (Affinity Capture-Western), ACSS3 (Affinity Capture-MS), ACSS3 (Affinity Capture-MS), LEFTY2 (Two-hybrid)

ESM2 similar proteins: A0A0G2K047, A0KNI2, A1U2S9, A4G3L8, A4SJM6, A6UED8, A6WXV8, A7MB45, A8PDE3, B2JD61, B3PS41, B9DGD6, B9JEV4, B9JV43, C3MAS0, O13440, O60011, O68040, O94049, P16928, P16929, P31638, P36333, P52910, P78773, Q01574, Q01576, Q14DH7, Q27549, Q2K2T1, Q54Z60, Q554Z5, Q5REB8, Q6BQF2, Q6BS00, Q6FLU2, Q6FXI2, Q6MNF1, Q750T7, Q758X0

Diamond homologs: A0A0G2K047, A0B8F1, A0KNI2, A0L576, A0LG91, A0R5G1, A1SZA2, A1U2S9, A1UR36, A1UWN5, A2RYW5, A3MG40, A3P2K7, A4SJM6, A4WJG1, A5VSF3, A6UED8, A6WXV8, A7HSR8, A7IFD4, A7MB45, A9IYZ3, A9M849, A9W5V0, A9WWT6, B0S8X7, B0SRX5, B1M0M1, B1ZB59, B2IB12, B2JD61, B2S7N5, B3PS41, B5ZV36, B7KPN8, B8EPJ0, B8FIN2, B9JEV4, B9JV43, C0RF62

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
ACSS3	“up-regulates quantity”	acetyl-CoA(4-)	“chemical modification”
ACSS3	“down-regulates quantity”	acetate	“chemical modification”
ACSS3	“down-regulates quantity”	“coenzyme A(4-)”	“chemical modification”

Disease & clinical

Clinical variants and AI predictions

ClinVar

123 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	5
Likely pathogenic	1
Uncertain significance	95
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (6)

Variant ID	HGVS	Classification
155032	GRCh38/hg38 12q21.1-22(chr12:73485697-92795805)x1	Pathogenic
3063243	GRCh37/hg19 12q21.1-21.33(chr12:74887087-90469800)x1	Pathogenic
57584	GRCh38/hg38 12q15-21.31(chr12:70337484-81761145)x1	Pathogenic
59816	GRCh38/hg38 12q21.2-21.31(chr12:77564757-85370822)x3	Pathogenic
687328	GRCh37/hg19 12q21.2-22(chr12:77737623-94330526)x1	Pathogenic
152482	GRCh38/hg38 12q21.2-21.31(chr12:76566873-82021089)x1	Likely pathogenic

SpliceAI

4252 predictions. Top by Δscore:

Variant	Effect	Δscore
12:81109554:TTTCA:T	acceptor_loss	1.0000
12:81109555:TTCA:T	acceptor_loss	1.0000
12:81109557:CAG:C	acceptor_loss	1.0000
12:81109558:AGGTT:A	acceptor_loss	1.0000
12:81109559:GGT:G	acceptor_gain	1.0000
12:81109559:GGTTT:G	acceptor_gain	1.0000
12:81109700:AGCAG:A	donor_loss	1.0000
12:81109701:GCAG:G	donor_gain	1.0000
12:81109703:AG:A	donor_loss	1.0000
12:81109704:GG:G	donor_loss	1.0000
12:81109705:G:T	donor_loss	1.0000
12:81109706:T:A	donor_loss	1.0000
12:81151839:CTTA:C	acceptor_loss	1.0000
12:81151841:TA:T	acceptor_loss	1.0000
12:81151842:A:AG	acceptor_gain	1.0000
12:81151842:AG:A	acceptor_gain	1.0000
12:81151842:AGG:A	acceptor_gain	1.0000
12:81151842:AGGGT:A	acceptor_gain	1.0000
12:81151843:G:A	acceptor_gain	1.0000
12:81151843:G:GG	acceptor_gain	1.0000
12:81151843:GGG:G	acceptor_gain	1.0000
12:81151843:GGGT:G	acceptor_gain	1.0000
12:81151843:GGGTG:G	acceptor_gain	1.0000
12:81151921:AGAGG:A	donor_loss	1.0000
12:81151922:GAG:G	donor_gain	1.0000
12:81151922:GAGGT:G	donor_loss	1.0000
12:81151923:AGGTA:A	donor_loss	1.0000
12:81151924:GGTA:G	donor_loss	1.0000
12:81151925:G:T	donor_loss	1.0000
12:81151926:T:A	donor_loss	1.0000

AlphaMissense

4438 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:81134954:T:C	F199L	0.999
12:81134956:T:A	F199L	0.999
12:81134956:T:G	F199L	0.999
12:81152028:T:A	W344R	0.999
12:81152028:T:C	W344R	0.999
12:81152030:G:C	W344C	0.999
12:81152030:G:T	W344C	0.999
12:81199435:T:A	W449R	0.999
12:81199435:T:C	W449R	0.999
12:81233367:G:C	D539H	0.999
12:81109651:A:C	S135R	0.998
12:81109653:T:A	S135R	0.998
12:81109653:T:G	S135R	0.998
12:81134963:T:C	F202L	0.998
12:81134965:T:A	F202L	0.998
12:81134965:T:G	F202L	0.998
12:81152020:A:T	D341V	0.998
12:81233370:G:C	A540P	0.998
12:81233374:G:A	G541D	0.998
12:81233404:T:A	V551D	0.998
12:81253344:T:A	V586D	0.998
12:81109637:C:A	A130D	0.997
12:81152004:T:A	W336R	0.997
12:81152004:T:C	W336R	0.997
12:81152007:T:A	W337R	0.997
12:81152007:T:C	W337R	0.997
12:81152017:C:T	S340F	0.997
12:81152020:A:C	D341A	0.997
12:81152020:A:G	D341G	0.997
12:81152086:T:A	V363D	0.997

dbSNP variants (sampled 300 via entrez): RS1000012872 (12:81109449 G>A), RS1000024891 (12:81150623 A>G), RS1000028720 (12:81233825 A>T), RS1000031933 (12:81233564 C>T), RS1000037375 (12:81249370 T>G), RS1000079472 (12:81251297 T>C), RS1000082593 (12:81217623 A>G), RS1000084544 (12:81084016 A>G,T), RS1000097403 (12:81260754 G>T), RS1000102842 (12:81165319 C>T), RS1000107545 (12:81157814 A>G), RS1000157388 (12:81223316 C>A), RS1000190674 (12:81239580 C>T), RS1000194312 (12:81212838 C>T), RS1000228220 (12:81157057 T>C,G)

Disease associations

OMIM: gene MIM:614356 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST002046_3	Response to antidepressant treatment (citalopram)	4.000000e-06
GCST002359_6	Plasma amyloid beta peptide concentrations (ABx-42)	5.000000e-06
GCST002618_2	Age-related cataracts (age at onset)	6.000000e-07
GCST004639_34	Prudent dietary pattern	7.000000e-06
GCST008522_16	Bitter alcoholic beverage consumption	2.000000e-07
GCST008757_34	Alcohol consumption	2.000000e-09
GCST009180_7	Pars orbitalis volume	6.000000e-06
GCST009189_10	Lateral orbital frontal cortex volume	1.000000e-06
GCST009190_14	Medial orbital frontal cortex volume	1.000000e-07
GCST011122_73	Walking pace	3.000000e-10

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0005660	plasma beta-amyloid 1-42 measurement
EFO:0004847	age at onset
EFO:0008111	diet measurement
EFO:0010092	bitter alcoholic beverage consumption measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression	3
methylmercuric chloride	decreases expression	2
Acetaminophen	decreases expression	2
Arsenic	affects methylation	2
Cyclosporine	decreases expression	2
aristolochic acid I	decreases expression	1
dicrotophos	decreases expression	1
bisphenol A	affects expression	1
arsenite	increases methylation	1
sodium arsenite	increases expression	1
perfluorooctanoic acid	affects cotreatment, increases expression	1
potassium chromate(VI)	increases expression	1
lei gong teng	increases expression	1
epigallocatechin gallate	decreases expression	1
abrine	decreases expression	1
MRK 003	decreases expression	1
incobotulinumtoxinA	increases expression	1
Benzo(a)pyrene	decreases methylation, increases methylation	1
Calcitriol	affects cotreatment, increases expression	1
Cosmetics	affects cotreatment, increases expression	1
Coumestrol	decreases expression	1
Dimethyl Sulfoxide	increases expression	1
Doxorubicin	decreases expression	1
Estradiol	decreases expression	1
Flame Retardants	affects cotreatment, increases expression	1
Lead	affects expression	1
Mercuric Chloride	decreases expression	1
Nickel	decreases expression	1
Plasticizers	affects cotreatment, increases expression	1
Quercetin	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7JE	Ubigene A-549 ACSS3 KO	Cancer cell line	Male

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery